Ludwike W. M. van Kalmthout

Ludwike W. M. van Kalmthout

Auto-generated profile, based on publicly available information

Ludwike W. M. van Kalmthout

Department of Radiotherapy, University Medical Center Utrecht, Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in EJNMMI Research
Verified
Journal Article
Open access
LKLudwike W. M. van Kalmthout
Ludwike W. M. van Kalmthout
MLMarnix G. E. H. Lam
Marnix G. E. H. Lam
BKBart De Keizer
Bart De Keizer
GKGerard C. Krijger
Gerard C. Krijger
TVTessa F. T. Ververs
Tessa F. T. Ververs
ABArthur J. A. T. Braat
Arthur J. A. T. Braat
External cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Twenty-four patients were scanned with unilateral (solely left-sided) icepacks; 20 with bilateral icepacks; 45 without icepacks. Icepacks were applied approximately 30 minutes prior to tracer injection. PET/CT acquisition started 1 hour postinjection. Radiotracer uptake was measured in the parotid- and submandibular glands. When comparing the intervention group with the control group, uptake in the left parotid gland significantly differed: SUVmax: 11.07 ± 3.53 versus 12.95 ± 4.16; p = 0.02. SUVpeak: 9.91 ± 3.14 versus 11.45 ± 3.61; p = 0.04. SUVmax and SUVpeak were reduced with 14.52% and 13.45%. All other SUV values did not significantly differ. Patients with bilateral icepacks showed no significant differences in PSMA uptake compared to the control group (all: p > 0.05). Intra-patient analysis revealed some significant differences in SUVmax and SUVpeak between the cooled and non-cooled parotid gland (SUVmax: 11.12 ± 3.71 versus 12.69 ± 3.75; p = 0.00. SUVpeak: 9.93 ± 3.32 versus 11.25 ± 3.25; p = 0.00). Impact of icepacks on PSMA uptake seems to be limited to the parotid glands. As clinical relevance of these findings is debatable, structural application of icepacks in the setting of lutetium-177 PSMA therapy needs careful consideration.

1 June 2019 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
LKLudwike van Kalmthout
Ludwike van Kalmthout
ABArthur Braat
Arthur Braat
MLMarnix Lam
Marnix Lam
RLRachel van Leeuwaarde
Rachel van Leeuwaarde
GKGerard Krijger
Gerard Krijger
BKBart De Keizer
Bart De Keizer
Purpose: The present study summarizes the first experience with 177Lu-PSMA-617 (177Lu-PSMA) treatment in metastatic castration-resistant prostate cancer (PCa) in our institution. Methods: This was an analysis of the first 30 consecutive patients who underwent 177Lu-PSMA therapy. Biochemical response was defined as prostate-specific antigen decrease of 50% or greater. Clinical toxicity was based on standardized physician's report, and biochemical and hematological toxicity was graded according to the Common Toxicity Criteria for Adverse Events (CTCAE) criteria. Clinical response was objectified in terms of severity of pain and usage of analgesics after separate treatment cycles. Results: Thirty patients with advanced PCa received therapy cycles with 6 GBq 177Lu-PSMA (median, 4; range, 1–6). After the first cycle, usage of analgesics decreased in 45% of the patients. During treatment, maximum prostate-specific antigen decrease was 50% or greater and 90% or greater in 57% and 24% of the patients, respectively. Despite CTCAE grades III and IV anemia occurring in 2 patients (7%), all other newly originated biochemical toxicity was limited to maximum CTCAE grades I and II. Grade II xerostomia occurred in 17% of the patients. During a median follow-up length of 13.7 months (range, 9.8–32.3 months), median overall survival from start of the first therapy cycle was 11.3 months (range, 1.4–32.3 months). Conclusions: These results confirm the favorable safety and efficacy profile of 177Lu-PSMA, even up to 6 treatment cycles. Therefore, 177Lu-PSMA seems a promising therapeutic strategy for metastatic castration-resistant PCa patients. However, randomized controlled trials are warranted to obtain robust data.

13 August 2022 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
ESEsmée van der Sar
Esmée van der Sar
WKWillem R. Keusters
Willem R. Keusters
LKLudwike W. M. van Kalmthout
Ludwike W. M. van Kalmthout
ABArthur Johannes Anthonius Theodorus Braat
Arthur Johannes Anthonius Theodorus Braat
BKBart De Keizer
Bart De Keizer
HMHarm H. E. Van Melick
Harm H. E. Van Melick
Background: Despite its high specificity, PSMA PET/CT has a moderate to low sensitivity of 40–50% for pelvic lymph node detection, implicating that a negative PSMA PET/CT cannot rule out lymph node metastases. This study investigates a strategy of implementing PSMA PET/CT for initial prostate cancer staging and treatment planning compared to conventional diagnostics. In this PSMA PET/CT strategy, a bilateral extended pelvic lymph node dissection (ePLND) is only performed in case of a negative PSMA PET/CT; in case of a positive scan treatment planning is solely based on PSMA PET/CT results. Method: A decision table and lifetime state transition model were created. Quality-adjusted life years and health care costs were modelled over lifetime. Results: The PSMA PET/CT strategy of treatment planning based on initial staging with [68Ga]Ga-PSMA-11 PET/CT results in cost-savings of €674 and a small loss in quality of life (QoL), 0.011 QALY per patient. The positive effect of [68Ga]Ga-PSMA-11 PET/CT was caused by abandoning both an ePLND and unnecessary treatment in iM1 patients, saving costs and resulting in higher QoL. The negative effect was caused by lower QoL and high costs in the false palliative state, due to pN1lim patients (≤ 4 pelvic lymph node metastases) being falsely diagnosed as iN1ext (> 4 pelvic lymph node metastases). These patients received subsequently palliative treatment instead of potentially curative therapy. Conclusion: Initial staging and treatment planning based on [68Ga]Ga-PSMA-11 PET/CT saves cost but results in small QALY loss due to the rate of false positive findings.

26 August 2020 in Tijdschrift voor Urologie
Verified
Journal Article
Open access
PDF file
LKLudwike W. M. van Kalmthout
Ludwike W. M. van Kalmthout
ESEsmée C. A. van der Sar
Esmée C. A. van der Sar
ABArthur J. A. T. Braat
Arthur J. A. T. Braat
BKBart de Keizer
Bart de Keizer
MLMarnix G. E. H. Lam
Marnix G. E. H. Lam
Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors’ experiences on [177Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [177Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [177Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.

8 October 2018 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
LKLudwike van Kalmthout
Ludwike van Kalmthout
ASAnine Stam
Anine Stam
RGRenze Gans
Renze Gans
MLMarnix Lam
Marnix Lam
This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient presented with a slowly impairing, bilateral visual loss. This clinical presentation was most likely the result of the high intracranial pressure due to impediment of cerebrospinal fluid circulation, possibly related to obstructive dural thickness, being either caused by dural and/or leptomeningeal metastases of advanced mCRPC or by local radiation effects following lutetium-177-PSMA therapy. Describing this case, we aim to add to the discussion on177Lu-PSMA safety, in which prospective research will ultimately offer definite answers.

1 June 2021 in European Urology
Verified
Journal Article
Closed access
RHR. Hermsen
R. Hermsen
EWE.B.C. Wedick
E.B.C. Wedick
MVM.J.M. Vinken
M.J.M. Vinken
LKL.W.M. Van Kalmthout
L.W.M. Van Kalmthout
HKH.V.N. Küsters-Vandevelde
H.V.N. Küsters-Vandevelde
JBJ.P.A. Van Basten
J.P.A. Van Basten